467 related articles for article (PubMed ID: 32699351)
1. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
2. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
3. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
4. Renal Cell Carcinoma-Infiltrating CD3
Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
[TBL] [Abstract][Full Text] [Related]
5. γδ T cells and their potential for immunotherapy.
Wu YL; Ding YP; Tanaka Y; Shen LW; Wei CH; Minato N; Zhang W
Int J Biol Sci; 2014; 10(2):119-35. PubMed ID: 24520210
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.
Correia DV; Fogli M; Hudspeth K; da Silva MG; Mavilio D; Silva-Santos B
Blood; 2011 Jul; 118(4):992-1001. PubMed ID: 21633088
[TBL] [Abstract][Full Text] [Related]
7. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
8. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
9. Systemic β-Adrenergic Receptor Activation Augments the
Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
Front Immunol; 2019; 10():3082. PubMed ID: 32038628
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
[TBL] [Abstract][Full Text] [Related]
11. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?
Galati D; Zanotta S; Bocchino M; De Filippi R; Pinto A
Cancer Immunol Immunother; 2021 Jul; 70(7):1797-1809. PubMed ID: 33386466
[TBL] [Abstract][Full Text] [Related]
12. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity.
Chitadze G; Oberg HH; Wesch D; Kabelitz D
Trends Immunol; 2017 Sep; 38(9):668-678. PubMed ID: 28709825
[TBL] [Abstract][Full Text] [Related]
13. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
Paul S; Lal G
Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
15. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
Li Y; Li G; Zhang J; Wu X; Chen X
Front Immunol; 2020; 11():619954. PubMed ID: 33664732
[TBL] [Abstract][Full Text] [Related]
16. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
Front Immunol; 2018; 9():1990. PubMed ID: 30298063
[TBL] [Abstract][Full Text] [Related]
17. The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
Liu Y; Zhang C
Cells; 2020 May; 9(5):. PubMed ID: 32413966
[TBL] [Abstract][Full Text] [Related]
18. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
[TBL] [Abstract][Full Text] [Related]
19. Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.
Polito VA; Cristantielli R; Weber G; Del Bufalo F; Belardinilli T; Arnone CM; Petretto A; Antonucci L; Giorda E; Tumino N; Pitisci A; De Angelis B; Quintarelli C; Locatelli F; Caruana I
Front Immunol; 2019; 10():2717. PubMed ID: 31824502
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
